COMPANY PROFILE

Cambrian Genomics

Explore full profile

Biotechnology company which uses a novel, laser based technique to synthesize dna

San Francisco, United StatesFounded 2011Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2014

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cambrian Genomics

Cambrian Genomics operates in the cutting-edge field of genomics, focusing on the study and manipulation of DNA to understand and influence the genetic code that governs all living organisms. The company serves a diverse range of clients including academic researchers, pharmaceutical companies, and biotechnology firms. Cambrian Genomics leverages advanced technologies to decode and edit genomes, enabling breakthroughs in medical research, drug development, and personalized medicine. The company operates in the biotechnology and life sciences market, utilizing a business model that includes service contracts, licensing agreements, and product sales. Revenue is generated through the provision of genomic sequencing services, custom DNA synthesis, and proprietary genomic editing tools. Cambrian Genomics is at the forefront of genomic innovation, providing essential tools and services that drive advancements in understanding and manipulating genetic information.

Source: Dealroom company data

At a glance

Status: Closed
Founded: 2011
Headquarters: San Francisco, United States
Employees: 2
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Cambrian Genomics.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2014	$11M	$45M	Velos Partners	—
SEED✓Equity / VC	Sep 2013	—	—	TenOneTen Ventures · Techammer	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Cambrian Genomics website traffic

Latest recorded traffic for Cambrian Genomics is 740 monthly website visits, down 53.8% over the last three months. Cambrian Genomics's team grew 100% over the past year.

Latest monthly visits740 3-month web change-53.8% 1-year team growth+100%

Monthly website visitsOct 2017–Sep 2018

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational	839	$391M	$4.3B
GLGoPath LaboratoriesFully equipped, cap accredited and clia certified anatomic pathology, clinical pathology and molecular diagnostic laboratory	Indianapolis, United States	Operational
GHGenomic HealthAbout Genomic Health Genomic Health, Inc	Redwood City, United States	Acquired
CBChronix BiomedicalMolecular diagnostics company developing blood tests for monitoring minimal residual disease in cancer patients	San Jose, United States	Acquired
AKAKESOgenBiomarker, genomics, and pharmacogenomics contract research organization	Peachtree Corners, United States	Acquired
MIMIODxMIODx, a company working on biomarker diagnostics	San Jose, United States	Operational
PDPhthisis DiagnosticsMolecular diagnostics company developing products for various infectious diseases	Charlottesville, United States	Acquired
PRProstaGeneBiotechnology start up company that is developing technology based on patents	United States	Acquired